AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (445)	8/18/1997 7:26:00 AM
From: Henry Niman	of 2173

Andy, I think that the figures in the press release are correct: >>Despite the variability in insulin dosing, 46% of patients evaluable at 52 weeks had a statistically significant, 12-month reduction in HbA1c > 0.5% (p =0.0060) compared to 29% of placebo patients. << The above statement means that they are using a reduction in HbA1c of greater than 0.5% as an indication of a positive results. This is a very small improvement. Consequently, 29% of the placebo group was able to reduce HbA1c by 0.5% over a year's time by injecting saline several times a day. In contrast, 46% of the patients who injected pramlintide, reduced their HbA1c, by 0.5% or more. Thus the difference between the two groups was only 17%. In other words, 54% of the patients who injected Pramlintide couldn't get their HbA1c to even drop 0.5%. 29% could acheive this results by merely thinking that they were injecting the drug. 17% more could do it with the drug. As I said originally, even in type I patients the results were less than stellar.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next